These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7986727)

  • 1. Dose of desferrioxamine and evolution of HIV-1 infection in thalassaemic patients.
    Costagliola DG; de Montalembert M; Lefrère JJ; Briand C; Rebulla P; Baruchel S; Dessi C; Fondu P; Karagiorga M; Perrimond H
    Br J Haematol; 1994 Aug; 87(4):849-52. PubMed ID: 7986727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients.
    Salhi Y; Costagliola D; Rebulla P; Dessi C; Karagiorga M; Lena-Russo D; de Montalembert M; Girot R
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):473-8. PubMed ID: 9715844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased expression of c-myc oncoprotein by peripheral blood mononuclear cells in thalassaemia patients receiving desferrioxamine.
    Kyriakou D; Eliopoulos AG; Papadakis A; Alexandrakis M; Eliopoulos GD
    Eur J Haematol; 1998 Jan; 60(1):21-7. PubMed ID: 9451424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA; Taqi A; Deghaidi A
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of AIDS in HIV-1 infected thalassaemia patients. European and Mediterranean W.H.O. Working Group on Haemoglobinopathies and Cooleycare.
    Costagliola DG; Girot R; Rebulla P; Lefrère JJ
    Br J Haematol; 1992 May; 81(1):109-12. PubMed ID: 1520608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
    Mourad FH; Hoffbrand AV; Sheikh-Taha M; Koussa S; Khoriaty AI; Taher A
    Br J Haematol; 2003 Apr; 121(1):187-9. PubMed ID: 12670352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term follow-up and bone imaging in acquired osteochondrodysplasia in a female patient with thalassemia and desferrioxamine hypersensitivity].
    Mangiagli A; De Sanctis V; Campisi S; Di Silvestro G; Urso L
    Minerva Pediatr; 2000 Apr; 52(4):235-41. PubMed ID: 11995208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe infections in thalassaemic patients: prevalence and predisposing factors.
    Rahav G; Volach V; Shapiro M; Rund D; Rachmilewitz EA; Goldfarb A
    Br J Haematol; 2006 Jun; 133(6):667-74. PubMed ID: 16704445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Gao HY; Li Q; Chen JJ; Chen GF; Li CG
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload.
    Araujo A; Kosaryan M; MacDowell A; Wickens D; Puri S; Wonke B; Hoffbrand AV
    Br J Haematol; 1996 Jun; 93(4):835-7. PubMed ID: 8703813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative evaluation of the retinal venous tortuosity in chronic anaemic patients affected by beta-thalassaemia major.
    Incorvaia C; Parmeggiani F; Costagliola C; Perri P; D'Angelo S; Sebastiani A
    Eye (Lond); 2003 Apr; 17(3):324-9. PubMed ID: 12724693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine.
    Rego EM; Neto EB; Simões BP; Zago MA
    Am J Hematol; 1998 Aug; 58(4):340-1. PubMed ID: 9692403
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
    Wu KH; Chang JS; Tsai CH; Peng CT
    Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined versus monotherapy or concurrent therapy for treatment of thalassaemia.
    Song TS; Hsieh YW; Peng CT; Chen TL; Lee HZ; Chung JG; Hour MJ
    In Vivo; 2014; 28(4):645-9. PubMed ID: 24982236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short stature and body proportion in thalassaemia.
    Caruso-Nicoletti M; De Sanctis V; Capra M; Cardinale G; Cuccia L; Di Gregorio F; Filosa A; Galati MC; Lauriola A; Malizia R; Mangiagli A; Massolo F; Mastrangelo C; Meo A; Messina MF; Ponzi G; Raiola G; Ruggiero L; Tamborino G; Saviano A
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():811-6. PubMed ID: 10091151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload.
    Aydinok Y; Unal S; Oymak Y; Vergin C; Türker ZD; Yildiz D; Yesilipek A
    Eur J Haematol; 2012 May; 88(5):431-8. PubMed ID: 22335829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of chelators on zinc levels in patients with thalassemia major.
    Erdoğan E; Canatan D; Ormeci AR; Vural H; Aylak F
    J Trace Elem Med Biol; 2013 Apr; 27(2):109-11. PubMed ID: 23164519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.